[1]李菊明,黄宇旻,马益民,等.吉西他滨联合多西他赛二线治疗进展期软组织肉瘤临床观察[J].陕西医学杂志,2019,(3):377-379.
点击复制

吉西他滨联合多西他赛二线治疗进展期软组织肉瘤临床观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年3期
页码:
377-379
栏目:
药物与临床
出版日期:
2019-03-05

文章信息/Info

文章编号:
DOI:10.3969/j.issn.10007377.2019.03.025
作者:
李菊明; 黄宇旻; 马益民; 高 峰; 韦永中
南京医科大学第一附属医院骨科（南京100292）
关键词:
吉西他滨; 多西他赛; 进展期; 软组织肉瘤
分类号:
R738.6
文献标志码:
A
摘要:
摘 要 目的：观察吉西他滨联合多西他赛（GT）方案治疗进展期软组织肉瘤（STS）患者的疗效和不良反应。方法：回顾收集进展期软组织肉瘤患者17例，采用GT方案治疗，观察GT方案治疗进展期软组织肉瘤的疗效和不良反应。结果：17例进展期软组织肉瘤患者共完成96个化疗周期，中位化疗周期数为6个（范围：1～9个）。3例（17.6%）患者为部分缓解，5例（29.4%）为疾病稳定，9例（53.0%）为疾病进展，疾病控制率达47.0%。中位无进展生存期为6.5个月，中位生存期为20.0个月。最常见的不良反应为骨髓抑制，其中3/4级不良反应主要为白细胞/中性粒细胞减少4例（23.5%）、血小板减少1例（5.9%）、贫血1例（5.9%）。无因不良反应导致退组或致死病例。结论：GT方案治疗进展期软组织肉瘤的疗效肯定且不良反应轻微可控，患者耐受性良好。

参考文献/References:

[1] 〖JP2〗Clark MA, Fisher C, Judson I, et al. Softtissue sarcomas in adults［J］. N Engl J Med, 2005, 353(7):701711.〖JP〗
[2] Hensley ML, Maki R, Venkatraman E,et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase Ⅱ trial [J].J Clin Oncol, 2002,20(12):28242831. \[3\] Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase Ⅱ study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)[J]. Oncologist , 2012, 17(9):12131220. \[4\] 〖JP2〗GarciaCarbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy［J］. J Clin Oncol, 2004, 22(8): 14801490.〖JP〗 \[5\] Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma[J].Cancer, 2003, 98(5):10291038.
[6] World Health Organization. Pathology and genetics of tumours of soft tissue and bone［M］. Lyon: IARC Press, 2002: 8690.
[7] Santoro A，Tursz T，Mouridsen H，et al．Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in firstline treatment of advanced soft tissue sarcomas：a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J]．J Clin Oncol，1995，13(7)：15371545.
[8] 〖JP3〗Edmonson JH，Ryan LM，Blum RH，et al．Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin，doxorubicin, and cisplatin against advanced soft tissue sarcomas[J]．J Clin Oncol，1993，1l(7)：12691275.〖JP〗
[9] Oosten AW, Seynaeve C, Schmitz PI, et al. Outcomes of firstline chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and nonuterine origin[J]. Sarcoma ,2009,2009:348910348916. 
[10] Penel N, Italiano A, Isambert N, et al. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin containing chemotherapy[J]. Ann Oncol , 2010,21(6):13611365.
[11] 〖JP2〗Takana T, Niikura H, Ito K, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan[J]. Int J Oncol, 2014,19(5):897905.

更新日期/Last Update: 2019-03-15